Exciting news! IVRS AB is proud to be a key partner in the NIAC consortium, recently awarded a €1.36M Eurostars grant for groundbreaking renal cell carcinoma (RCC) research!
We’ll be leveraging our cutting-edge in vivo RCC models and whole-body 3D imaging to evaluate a novel inhibitor developed by AtG Therapeutics. This promising therapeutic could offer new hope for patients resistant to current treatments.
At IVRS AB, we are committed to accelerating oncological drug development and unlocking new treatments for tumor progression and metastasis. This collaboration, alongside AtG Therapeutics, DOPPL SA, and the University of Bern, exemplifies the power of partnership in driving innovation.
#RenalCellCarcinoma #RCC #Oncology #DrugDevelopment #Eurostars #Innovation #IVRSAB #AtGTherapeutics #DOPPLSA #UniversityofBern #3DImaging #InVivoModels #PrecisionMedicine #CancerResearch
